Farmak International Showcases Injectable Medicines at Global Pharmaceutical Exhibition
The CPhI Worldwide 2025 global pharmaceutical exhibition was held in Frankfurt, bringing together over 2,400 participants from 160 countries and 62,000 visitors this year.
CPhI is one of the key events in the global pharmaceutical industry. It unites specialists, experts, and companies from different countries to exchange experience, establish partnerships, and present innovations across the full drug development cycle — from active substance synthesis to finished product manufacturing. Leading international pharmaceutical corporations such as Pfizer, Novartis, Roche, Sanofi, Johnson & Johnson, AstraZeneca, Bayer, GSK, Merck, Takeda, and others traditionally participate.
At the Farmak International booth, a wide range of products from the Farmak Group was showcased across various therapeutic areas, including injectable medicines, as well as drugs for the treatment of metabolic and endocrine disorders, psychiatry, oncology, immunology, anesthesia, and intensive care.
During the exhibition, Farmak International also presented the company’s new facility in Spain for the production of complex injectable medicines. The plant will manufacture drugs in the form of solutions and suspensions, packaged in vials and prefilled syringes.
Today, the Farmak Group is a global pharmaceutical business, founded in Ukraine in 1925, with manufacturing facilities in Ukraine and Spain, as well as subsidiaries and representative offices in 11 countries worldwide. Its products are exported to over 60 countries, including 15 EU countries, and are manufactured in compliance with EU GMP (Good Manufacturing Practice) standards.
Farmak International oversees the Group’s global operations, asset management, and expansion into international markets.
